Sign In
Buy CTOS
$9.83
+0.0700 (+0.717%)
At Close: Jun 03, 2026
Should Value Investors Buy Custom Truck One Source (CTOS) Stock?
10:45am, Monday, 17'th Mar 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Custom Truck One Source Showcases Load King Turbo Loader at WWETT 2025
10:00am, Friday, 07'th Mar 2025
KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS), a leading provider of specialty equipment to the electric utility, telecom, rail, and other infrastructure-related end ma
Custom Truck One Source, Inc. (CTOS) Q4 2024 Earnings Call Transcript
12:16pm, Wednesday, 05'th Mar 2025
Custom Truck One Source, Inc. (NYSE:CTOS ) Q4 2024 Results Conference Call March 5, 2025 9:00 AM ET Company Participants Brian Perman - Vice President, Investor Relations Ryan McMonagle - CEO Christop
Custom Truck One Source, Inc. (CTOS) Q4 Earnings Meet Estimates
06:55pm, Tuesday, 04'th Mar 2025
Custom Truck One Source, Inc. (CTOS) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago.
Custom Truck One Source, Inc. Reports Fourth Quarter and Full-Year 2024 Results
04:10pm, Tuesday, 04'th Mar 2025
KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS), a leading provider of specialty equipment to the electric utility, telecom, rail, and other infrastructure-related end ma
Custom Truck One Source to Participate in the 2025 J.P. Morgan Industrials Conference
06:30am, Monday, 03'rd Mar 2025
KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS) today announced that Chief Executive Officer, Ryan McMonagle, and Chief Financial Officer, Chris Eperjesy, will present an
Are Investors Undervaluing Custom Truck One Source (CTOS) Right Now?
10:45am, Friday, 21'st Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Custom Truck One Source Announces Fourth Quarter and Full-Year 2024 Earnings Release and Conference Call
04:10pm, Tuesday, 11'th Feb 2025
KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS) today announced it will release financial results for the fourth quarter and full year 2024 after the market close on Tues
Insider Buying Surges in February, Especially in These 6 Stocks
08:45am, Sunday, 09'th Feb 2025
In January, the number of notable insider purchases was somewhat muted.
Should Value Investors Buy Custom Truck One Source (CTOS) Stock?
10:45am, Wednesday, 05'th Feb 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Are Auto-Tires-Trucks Stocks Lagging Custom Truck One Source (CTOS) This Year?
10:41am, Wednesday, 05'th Feb 2025
Here is how Custom Truck One Source, Inc. (CTOS) and Garrett Motion (GTX) have performed compared to their sector so far this year.
Custom Truck One Source: My Downgrade To Buy Reflects State Of Demand
05:02am, Wednesday, 29'th Jan 2025
Custom Truck One Source: My Downgrade To Buy Reflects State Of Demand
Are Investors Undervaluing Custom Truck One Source (CTOS) Right Now?
10:45am, Monday, 20'th Jan 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Custom Truck One Source to Participate in the BofA Securities 2024 Leveraged Finance Conference
04:10pm, Thursday, 21'st Nov 2024
KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS) today announced that President and Chief Executive Officer, Ryan McMonagle, and Chief Financial Officer, Chris Eperjesy, w
Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving I
